Company
Vertex Pharmaceuticals Incorporated
Headquarters: Boston, MA, United States
Founded: 1989
Employees: 3,900
CEO: Dr. Reshma Kewalramani FASN, M.D.
Market Cap
$121.36 Billion
USD as of July 1, 2024
Vertex Pharmaceuticals Incorporated Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Company Description
Vertex Pharmaceuticals Incorporated is a pharmaceuticals and biotherapeutics company. It notably produces drugs and genetic therapies for cystic fibrosis and other skin conditions, such as pain, sickle cell disease, beta-thalassemia, hormonal deficiencies, kidney diseases, Duchenne muscular dystrophy, and diabetes.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Moderna, Inc. | $44.44 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Vertex Pharmaceuticals Incorporated has the following listings and related stock indices.
Stock: NASDAQ: VRTX wb_incandescent
Stock: FSX: VX1 wb_incandescent
Product & Services
Pharmaceuticals
Key People
Reshma Kewalramani, M. D., president and CEO Stuart A. Arbuckle, executive vice president and chief commercial officer Michael J. Parini, executive vice president and chief legal, administrative and business development officer Jeffrey Leiden, M. D., Ph D, executive chairman David Altshuler, M. D., Ph D, executive vice president, global research and chief scientific officer Amit K. Sachdev, executive vice president and chief patient officer
Financials
Revenue: US$3.04 billion (2018)